Publications

Everolimus (Eve) plus Letrozole (Let) in Patients (Pts) with Estrogen Receptor-Positive (Er plus ), Human Epidermal Growth Factor Receptor 2-Negative (Her2-) Advanced Breast Cancer (Abc): Progression-Free Survival (Pfs) Subgroup Analyses in Bolero-4

AuthID
P-00N-2XN

Author(s)

Bachelot, T

Royce, M

Villanueva, C

Melo Cruz, FM

Hegg, R

Falkson, C

Jeong, J

Srimuninnimit, V

Arce, CH

Ridolfi, A

Lin, C

Gradishar, W

Ozguroglu, M

Cardoso, F

Azevedo, S

Document Type

Abstract

Year published

2017

Published

in ANNALS OF ONCOLOGY, ISSN: 0923-7534

Volume: 28

Conference

42Nd European-Society-For-Medical-Oncology Congress (Esmo), Date: SEP 08-12, 2017, Location: Madrid, SPAIN, Sponsors: European Soc Med Oncol

Indexing

Wos^®

Metadata
Sources

Publication Identifiers

Wos: WOS:000411324000233

Source Identifiers

ISSN: 0923-7534

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Everolimus (Eve) plus Letrozole (Let) in Patients (Pts) with Estrogen Receptor-Positive (Er plus ), Human Epidermal Growth Factor Receptor 2-Negative (Her2-) Advanced Breast Cancer (Abc): Progression-Free Survival (Pfs) Subgroup Analyses in Bolero-4

Useful Links

Get Help

Federated Authentication (Click on the image)

Everolimus (Eve) plus Letrozole (Let) in Patients (Pts) with Estrogen Receptor-Positive (Er plus ), Human Epidermal Growth Factor Receptor 2-Negative (Her2-) Advanced Breast Cancer (Abc): Progression-Free Survival (Pfs) Subgroup Analyses in Bolero-4

Useful Links

Get Help